ImmuniT Research
ImmuniT Research Inc. is dedicated to quantifying and monitoring immunity to solve global health issues. They develop technologies to measure immune responses, build immune data platforms, and support the development of diagnostics, therapeutics, and preventive methods. Their mission is to harness the power of immunity to eradicate diseases and improve human health.
Industries
Nr. of Employees
small (1-50)
ImmuniT Research
4-3-17 Shinjuku Shinjuku-ku, Tokyo 160-0022, Japan, FORECAST SHINJUKU SOUTH 3F
Products
IMTR001 (blood-based diagnostic for checkpoint inhibitors)
A blood-based diagnostic method that assesses peripheral lymphocyte subpopulations to pre-predict efficacy of PD-1 antibody therapy.
IMTR002 (Th7R biomarker)
Biomarker based on a CD4+ T‑cell subset (Th7R; CCR4- CCR6+ CD4+ T cells) for predicting response to PD-1/PD-L1 inhibitors using blood.
IMTR003 (COVID-19 severity biomarker)
Blood-immune-cell–based biomarker intended to predict risk of pneumonia severity in COVID-19 patients.
IMTR004 (diagnostic development, unrevealed target)
Preclinical diagnostic development program (details unrevealed).
IMTR001 (blood-based diagnostic for checkpoint inhibitors)
A blood-based diagnostic method that assesses peripheral lymphocyte subpopulations to pre-predict efficacy of PD-1 antibody therapy.
IMTR002 (Th7R biomarker)
Biomarker based on a CD4+ T‑cell subset (Th7R; CCR4- CCR6+ CD4+ T cells) for predicting response to PD-1/PD-L1 inhibitors using blood.
IMTR003 (COVID-19 severity biomarker)
Blood-immune-cell–based biomarker intended to predict risk of pneumonia severity in COVID-19 patients.
IMTR004 (diagnostic development, unrevealed target)
Preclinical diagnostic development program (details unrevealed).
Services
Support across drug-development stages including target discovery, validation, compound verification, and clinical-trial optimization using immune data and analytic methods.
Build partner-specific immune profiling systems by ingesting partner FCS/WSP and medical data and applying proprietary database and algorithms.
Outsourced research services and database development for studies related to immunotherapies and immunological biomarkers.
Platform-driven service to quantify and monitor individual immune status and provide lifestyle guidance for health management.
Support across drug-development stages including target discovery, validation, compound verification, and clinical-trial optimization using immune data and analytic methods.
Build partner-specific immune profiling systems by ingesting partner FCS/WSP and medical data and applying proprietary database and algorithms.
Outsourced research services and database development for studies related to immunotherapies and immunological biomarkers.
Platform-driven service to quantify and monitor individual immune status and provide lifestyle guidance for health management.
Expertise Areas
- Biomarker discovery and validation
- Immune profiling and immunophenotyping
- Single-cell gene-expression analysis
- Flow-cytometry data analysis and automation
Key Technologies
- Single-cell RNA sequencing
- Flow cytometry (FCS/WSP data analysis)
- Peripheral blood immunophenotyping
- Immune-profiling analytics and databases
News & Updates
Research presentation on Th7R cells and cancer immunity.
Patent decision regarding cell identification technology.
Company headquarters moved to a new location.
Participation in BioJapan 2018 as an exhibitor.
License agreement for blood test-based prediction of immunotherapy effects.
License agreement for cancer biomarkers.
Research presentation on Th7R cells and cancer immunity.
Patent decision regarding cell identification technology.
Company headquarters moved to a new location.
Participation in BioJapan 2018 as an exhibitor.
License agreement for blood test-based prediction of immunotherapy effects.
License agreement for cancer biomarkers.